Cardiopulmonary Bypass Equipment Market is estimated to be valued at USD 217.2 Mn in 2026 and is expected to reach USD 267.2 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 3.0% from 2026 to 2033. The market has been driven to a large extent by the increasing prevalence of cardiovascular diseases, an aging population, and cardiac surgeries. The healthcare organizations have started making use of cardiopulmonary bypass machines that are technically advanced in nature, so as to enhance their success rates as well as ensure improved safety of patients while carrying out more complicated cardiac surgeries. Technical advancements like portable heart-lung machines, advanced oxygenators, monitoring systems, and cardiac surgery technology have played a crucial part in driving the market.
The market can be characterized by the introduction of new perfusion technologies, hemodynamic monitoring capabilities, and the use of digital products in heart surgery procedures. Nowadays, manufacturers are interested in creating better, more effective, and more convenient cardiopulmonary bypass systems to reduce the number of complications and improve the efficiency of the procedure. Nevertheless, high prices for medical devices, a heavy regulatory environment, and the risk of complications from bypass procedures are barriers to market development. The opportunities of the market are the introduction of new artificial intelligence-based perfusion devices and new generation oxygenators.
The Single Roller Pump category is estimated to lead in terms of market share and holds a share of around 61.6% of the overall cardiopulmonary bypass equipment market in 2026. The leading position of the segment is mainly driven by its long-term utilization by cardiac surgeons, its clinical effectiveness, low cost when compared to other pumps, and wide availability around the world.
On a geographical basis, North America is expected to maintain its leading position in the global cardiopulmonary bypass equipment market in terms of market share, holding an approximate share of 40.7%. The dominant position is aided by the availability of advanced cardiac treatment facilities, established centers for transplantation and cardiac surgeries, supportive reimbursement scenario, and increasing knowledge about advanced cardiac therapies. The U.S. will continue to hold a leading position among the North American markets because of the large number of cardiac surgeries performed there.
Company Profiles
-
Medtronic plc
Company Overview
- Headquarters: Dublin, Ireland
• Establishment Year: 1949
• Employee Strength: Approximately 95,000+ employees
• Leadership: Geoff Martha, Chairman and CEO
• Core Services/Products: Cardiopulmonary bypass systems, Advanced Hemodynamic Monitoring (AHM) systems, oxygenators, perfusion technologies, cardiovascular devices, and patient monitoring solutions.
• Geographic Presence: Operations in more than 150 countries worldwide.
SWOT Analysis
- Strengths
- Industry leader in terms of technologies for cardiovascular and medical devices
- Strong Research and development capabilities and an extensive range of products for cardiovascular systems
- Weaknesses
- Dependence on regulations within the healthcare industry
- Hard to manage a diverse product range
- Opportunities
- Increase in minimally invasive heart surgery
- Building up of cardiac facilities in developing countries
- Threats
- Competing with major medical devices manufacturing companies
- Pricing and regulatory issues
-
LivaNova PLC
Company Overview
- Headquarters: London, U.K.
• Establishment Year: 2015 (following the merger of Sorin Group and Cyberonics)
• Employee Strength: Approximately 3,500+ employees
• Leadership: Vladimir Makatsaria, CEO
• Core Services/Products: Essenz Heart-Lung Machine, cardiopulmonary bypass systems, oxygenators, perfusion technologies, and cardiovascular surgery solutions.
• Geographic Presence: Operations in more than 100 countries.
SWOT Analysis
- Strengths
- Unmatched expertise in the field of cardiopulmonary bypass and perfusion machines
- Well-built brand image in the cardiac surgery market
- Weaknesses
- Smaller market presence compared to other diversified medical device companies
- Highly dependent on the cardiovascular product line
- Opportunities
- Increasing number of cardiac surgery patients worldwide
- Growing need for perfusion machines
- Threats
- Competitors in the form of multinationals
- Regulatory compliance and approvals
-
MAQUET Holding B.V. & Co. KG (Getinge Group)
Company Overview
- Headquarters: Rastatt, Germany
• Establishment Year: 1838
• Employee Strength: Approximately 12,000+ employees (Getinge Group)
• Leadership: Managed under the Getinge Group executive leadership
• Core Services/Products: Cardiohelp systems, cardiopulmonary bypass equipment, extracorporeal life support systems, surgical workstations, and critical care solutions.
• Geographic Presence: Presence in more than 100 countries worldwide.
SWOT Analysis
- Strengths
- Strong brand awareness in cardiac surgery and critical care
- Wide variety of cardiovascular and surgical products
- Weaknesses
- Costly surgeries and production
- Reliance on budgets for hospitals’ capital expenditures
- Opportunities
- Increasing need for portable bypass and support systems
- Increasing numbers of specialized cardiac surgery centers globally
- Threats
- Growing competition from sophisticated medical technology providers
- Tightened health care budgets in some regions
-
Terumo Corporation
Company Overview
- Headquarters: Tokyo, Japan
• Establishment Year: 1921
• Employee Strength: Approximately 30,000+ employees
• Leadership: Shinjiro Sato, President and CEO
• Core Services/Products: Cardiopulmonary bypass equipment, oxygenators, blood management systems, perfusion technologies, cardiovascular devices, and interventional solutions.
• Geographic Presence: Operations in more than 160 countries worldwide.
SWOT Analysis
- Strengths
- Competent in cardiac and blood management technologies
- Extensive distribution network in various parts of the world and different medical devices
- Weaknesses
- Foreign exchange risks in the operation of the company in several countries
- Complex global operations
- Opportunities
- Increasing demand for heart surgeries in various parts of the world
- Healthcare expenditures in developing countries
- Threats
- Regulatory risks in operating in various territories
- Price pressure from competing companies that manufacture medical devices
-
Braile Biomedica
Company Overview
- Headquarters: São José do Rio Preto, Brazil
• Establishment Year: 1977
• Employee Strength: Approximately 1,000+ employees
• Leadership: Executive Leadership Team, Braile Biomedica
• Core Services/Products: Cardiopulmonary bypass equipment, oxygenators, heart valves, cardiovascular implants, and surgical instruments.
• Geographic Presence: Presence in more than 60 countries.
SWOT Analysis
- Strengths
- Possessing extensive knowledge about cardiovascular medical devices
- Presence in the Latin American healthcare industry
- Weaknesses
- Relatively small geographical market compared to other MNCs
- Limited capital in comparison to market leaders
- Opportunities
- Expanding into other markets
- Rising demand for cost-effective cardiac surgical devices
- Threats
- Strong competition from foreign cardiovascular device manufacturers
- Supply chain challenges and changing regulations
